Bharat Parenterals Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,318 Cr
- ROE
- -2.54%
- Price to sales
- 4.09
- Debt to equity
- 0.45
- 52W high / low
- ₹2,150 / ₹890
- Sales growth (5Y)
- 11.04%
- EBITDA margin
- 3.27%
- Net profit margin
- -7.99%
- Promoter holding
- 67.20%
- Sales (last year)
- ₹323 Cr
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]
Guidance scorecard · Q1 FY27 call
What Bharat Parenterals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
20–40%Ask what Bharat Parenterals Ltd said on revenue →
Full Q4 FY26 analysisMarginsQ4 FY26 call
Up 2%+See what Bharat Parenterals Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility.
- As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget).
- Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028.
- The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29.
2 more points from Bharat Parenterals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what Bharat Parenterals Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
- The standalone business has an order book of INR 171 crores, providing reasonable visibility for FY '27.
- The $27 million ($27 million approx.) tender order for high-demand pharmaceutical products in the standalone business was delayed but has started supply in 2026, with 90% expected to be covered within the year.
- Innoxel has 20 targeted new partner deals in the pipeline, with 10 in advanced stages of discussions and due diligence.
- Innoxel expects to file 10 new products in FY '27.
2 more points from Bharat Parenterals Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Bharat Parenterals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingBharat Parenterals Ltd announcements
All announcements →- Fundraise / allotmentNotableBharat Parenterals Limited announces shareholder approval of two special resolutions
Financials of Bharat Parenterals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Bharat Parenterals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 50.97 | 69.91 | 59.81 | 59.82 | 67.82 | 92.51 | 71.63 | 72.26 | 103.98 | 116.00 | 64.62 | 65.19 | 99.62 |
| Expenses + | 44.75 | 59.46 | 55.49 | 53.21 | 66.82 | 88.02 | 79.29 | 68.62 | 101.75 | 102.22 | 63.79 | 63.45 | 100.14 |
| Operating Profit | 6.22 | 10.45 | 4.32 | 6.61 | 1.00 | 4.49 | -7.66 | 3.64 | 2.23 | 13.78 | 0.83 | 1.74 | -0.52 |
| OPM % | 12.20% | 14.95% | 7.22% | 11.05% | 1.47% | 4.85% | -10.69% | 5.04% | 2.14% | 11.88% | 1.28% | 2.67% | -0.52% |
| Other Income + | 0.31 | 2.10 | 2.60 | 1.26 | 2.64 | 2.54 | 4.21 | 2.94 | 1.93 | 1.06 | 3.53 | 1.33 | 3.63 |
| Interest | 0.80 | 0.89 | 0.63 | 0.58 | 1.13 | 2.77 | 2.91 | 3.33 | 3.94 | 3.69 | 3.11 | 2.90 | 2.85 |
| Depreciation | 1.44 | 1.58 | 1.75 | 1.82 | 3.87 | 9.03 | 9.01 | 8.76 | 8.52 | 8.60 | 8.56 | 8.46 | 8.63 |
| Profit before tax | 4.29 | 10.08 | 4.54 | 5.47 | -1.36 | -4.77 | -15.37 | -5.51 | -8.30 | 2.55 | -7.31 | -8.29 | -8.37 |
| Tax % | 47.09% | 30.46% | 46.48% | 33.46% | 88.24% | 85.32% | 13.92% | 43.01% | 13.61% | 134.12% | 17.65% | 16.77% | -2.51% |
| Net Profit + | 2.27 | 7.01 | 2.43 | 3.64 | -2.56 | -8.84 | -17.51 | -7.88 | -9.44 | -0.87 | -8.60 | -9.67 | -8.16 |
| EPS in Rs | 4.31 | 13.02 | 6.05 | 6.50 | -0.52 | 1.96 | -11.50 | -2.42 | -6.86 | 11.94 | -10.49 | -6.37 | -6.96 |
Financials of Bharat Parenterals Ltd
Profit & Loss
Annual income statement trend
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 124 | 111 | 137 | 220 | 228 | 205 | 212 | 218 | 261 | 340 | 345 |
| Expenses + | 114 | 105 | 124 | 191 | 200 | 179 | 183 | 198 | 234 | 337 | 330 |
| Operating Profit | 10 | 7 | 12 | 29 | 28 | 25 | 29 | 20 | 27 | 4 | 16 |
| OPM % | 8% | 6% | 9% | 13% | 12% | 12% | 14% | 9% | 10% | 1% | 5% |
| Other Income + | 5 | 8 | 7 | 13 | 11 | 9 | 7 | 12 | 5 | 11 | 10 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 13 | 13 |
| Depreciation | 4 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 9 | 35 | 34 |
| Profit before tax | 9 | 7 | 13 | 35 | 33 | 27 | 28 | 24 | 19 | -34 | -21 |
| Tax % | 31% | 8% | 29% | 39% | 26% | 25% | 25% | 33% | 44% | 29% | 27% |
| Net Profit + | 6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | 11 | -44 | -27 |
| EPS in Rs | 11.26 | 12.03 | 15.92 | 37.09 | 42.13 | 35.59 | 36.45 | 28.47 | 24.95 | -18.33 | -11.88 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 3% | 4% | -5% | -8% |
Financials of Bharat Parenterals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 |
| Reserves | 51 | 58 | 67 | 88 | 112 | 138 | 160 | 177 | 191 | 324 | 315 |
| Borrowings + | 19 | 6 | 9 | 5 | 1 | 12 | 18 | 50 | 158 | 180 | 146 |
| Other Liabilities + | 44 | 40 | 50 | 60 | 68 | 43 | 42 | 118 | 149 | 138 | 145 |
| Total Liabilities | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 | 613 |
| Fixed Assets + | 35 | 31 | 34 | 35 | 33 | 45 | 41 | 42 | 211 | 252 | 256 |
| CWIP | 0 | 0 | 0 | 1 | 12 | 0 | 26 | 99 | 25 | 31 | 34 |
| Investments | 0 | 1 | 1 | 1 | 0 | 43 | 11 | 0 | 0 | 5 | 6 |
| Other Assets + | 85 | 79 | 98 | 121 | 142 | 111 | 148 | 209 | 268 | 360 | 317 |
| Total Assets | 120 | 110 | 132 | 159 | 188 | 199 | 226 | 350 | 504 | 649 | 613 |
Financials of Bharat Parenterals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -2 | 6 | 20 | 14 | 24 | -1 | 22 | -5 | -27 | 38 |
| Cash from Investing Activity + | 0 | -2 | -8 | -9 | -13 | -43 | -7 | -78 | -105 | -137 | 9 |
| Cash from Financing Activity + | 0 | -8 | 4 | -4 | -3 | 10 | 9 | 61 | 110 | 156 | -47 |
| Net Cash Flow | 0 | -11 | 2 | 7 | -1 | -8 | 2 | 4 | 1 | -8 | 1 |
| Free Cash Flow | 0 | -4 | -2 | 12 | -0 | 24 | -40 | -68 | -108 | -56 | -1 |
| CFO/OP | 0% | -8% | 73% | 107% | 87% | 123% | 16% | 150% | 18% | -444% | 305% |
Financials of Bharat Parenterals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 130 | 143 | 157 | 106 | 127 | 121 | 126 | 188 | 198 | 184 | 159 |
| Inventory Days | 62 | 70 | 60 | 59 | 71 | 61 | 56 | 100 | 142 | 142 | 162 |
| Days Payable | 171 | 168 | 110 | 83 | 104 | 71 | 64 | 136 | 137 | 146 | 122 |
| Cash Conversion Cycle | 21 | 45 | 107 | 82 | 93 | 111 | 118 | 152 | 202 | 180 | 199 |
| Working Capital Days | 8 | 64 | 78 | 73 | 89 | 106 | 148 | 91 | 81 | 79 | 149 |
| ROCE % | 11% | 18% | 39% | 31% | 20% | 17% | 11% | 7% | -4% | -2% |
Guidance history
How Bharat Parenterals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 20–40% | Up 2%+ | Planned | — | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | Planned | Rising |
| Q4 FY25 call → | 20–40% | Flat | Planned | None planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
89 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +58.1% | 87% |
| Last 6 months | +58.2% | 91% |
| Last 3 months | +29.2% | 91% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Bharat Parenterals Ltd: 0.4 × 87 + 0.4 × 91 + 0.2 × 91 = 89.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Bharat Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY